We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Pfizer Czech Republic

Pharmaceutical > Czech Republic > Pfizer Czech Republic
Change Company
Pfizer Czech Republic

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic

Read more »
Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals

Buy all financials of Pfizer Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
                  6,807 3,118 5,407 4,947 3,122    
                  755 287 502 475 311    
                  303 63.4 170 170 98.2    
                  231 48.1 144 134 75.4    
                  25.2% 4.63% 11.1% 8.21% 5.24%    
                  4.45% 2.03% 3.15% 3.44% 3.15%    
                  3.40% 1.54% 2.67% 2.70% 2.41%    
                  253 203 183 170 121    

balance sheet

                  2,885 2,530 2,812 2,922 1,937    
                  16.5 9.46 7.30 99.1 197    
                  2,866 2,518 2,798 2,818 1,737    
                  1,034 1,043 1,562 1,696 1,180    
                  1,851 1,487 1,249 1,226 757    
                  0.438 0.438 0 0 0    
                  1,835 1,474 1,226 1,212 742    
                  2.16 -1.32 -0.141 -1.65 -0.037    
                  66.1% -8.43% -1.56% -16.8% -0.350%    
... ...             ... 4.09% 0.877% ... ... ... ...  

cash flow

            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    

Download Data
income statement Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
                  6,807 3,118 5,407 4,947 3,122    
                  6,051 2,831 4,905 4,472 2,811    
                  755 287 502 475 311    
                  389 127 266 271 175    
                  50.5 93.9 63.8 31.9 25.7    
                  316 66.4 173 172 110    
                  13.5 2.99 2.56 2.12 12.2    
                  303 63.4 170 170 98.2    
                  17.5 3.75 0.699 4.58 6.38    
                  -0.007 0.002 -8.21 0.063 0    
                  285 59.6 178 165 91.9    
                  53.8 11.6 33.5 31.6 16.5    
                  0 0 0 0 0    
                  231 48.1 144 134 75.4    

growth rates

...                 4.32% -54.2% 73.4% -8.51% -36.9%    
...                 -17.5% -49.8% 49.5% -8.06% -33.8%    
...                 93.1% -79.0% 160% -0.368% -35.9%    
...                 114% -79.1% 169% -0.115% -42.2%    
...                 132% -79.1% 198% -6.94% -44.5%    
...                 137% -79.2% 200% -7.25% -43.7%    

ratios

                  25.2% 4.63% 11.1% 8.21% 5.24%    
...                 13.9% 4.56% 18.1% 16.1% 7.83%    
                  11.1% 9.20% 9.29% 9.61% 9.96%    
                  4.64% 2.13% 3.20% 3.48% 3.54%    
                  4.45% 2.03% 3.15% 3.44% 3.15%    
                  3.40% 1.54% 2.67% 2.70% 2.41%    
... ...             ... 4.09% 0.877% ... ... ... ...  
                  2.16 -1.32 -0.141 -1.65 -0.037    

Download Data
balance sheet Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

                  16.5 9.46 7.30 99.1 197    
                  16.3 9.44 7.30 5.16 3.21    
                  0.181 0.026 0 93.9 194    
                  2,866 2,518 2,798 2,818 1,737    
                  959 933 1,095 813 716    
                  1,305 900 973 733 1,007    
                  172 87.9 24.3 284 4.12    
                  2,885 2,530 2,812 2,922 1,937    
                  1,034 1,043 1,562 1,696 1,180    
                  0 0 0 0 0    
                  1,851 1,487 1,249 1,226 757    
                  0.438 0.438 0 0 0    
                  0 0 0 0 0    
                  0 0 0 0 0    
                  1,835 1,474 1,226 1,212 742    
                  856 0 0 0 0    
                  734 1,280 1,039 1,023 616    
                  16.2 12.9 23.3 13.5 15.0    
                  2,885 2,530 2,812 2,922 1,937    

growth rates

...                 -3.91% -12.3% 11.1% 3.91% -33.7%    
...                 28.8% 0.865% 49.8% 8.56% -30.5%    
...                 -703% -113% -72.3% 1,069% -98.5%    
... ... ...       ...   ... ... -100% ... ... ... ... ...

ratios

                  856 0 0 0 0    
                  684 -87.9 -24.3 -284 -4.12    
                  1,530 552 1,028 523 1,107    
                  1,546 561 1,035 622 1,304    
                  66.1% -8.43% -1.56% -16.8% -0.350%    
... ...             ... 4.09% 0.877% ... ... ... ...  

Download Data
cash flow Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

                  231 48.1 144 134 75.4    
                  13.5 2.99 2.56 2.12 12.2    
...           ... ... ... ... ... ... ... ...    
...           ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ...    
...           ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    
            ... ... ... ... ... ... ... ...    

ratios

                  70.0 105 65.7 54.1 118    
                  57.8 120 81.5 66.3 92.9    
                  44.3 165 77.4 83.5 80.0    
                  83.6 60.5 69.8 36.9 131    
                  245 51.0 147 136 87.5    
            ... ... ... ... ... ... ... ...    

Download Data
other data Unit
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

                  7.86% 1.77% 5.40% 4.67% 3.10%    
                  11.1% 9.20% 9.29% 9.61% 9.96%    
                  253 203 183 170 121    
                  7,241 2,655 6,187 6,218 5,044    
                  128,064 51,930 121,053 132,894 120,395    
                  5.98% 4.14% 5.08% 5.68% 5.78%    
                  18.9% 19.4% 18.9% 19.1% 18.0%    
                  3,372 1,524 2,727 2,528 1,254    
            ... ... ... ... ... ... ... ...    
                  3,436 1,594 2,680 2,418 1,868    
                  50.5% 51.1% 49.6% 48.9% 59.8%    
                  3,395 1,502 2,710 2,524 2,824    
                  3,413 1,616 2,697 2,422 298    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Pfizer Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Pfizer Czech Republic's performance between 2002 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only

Read more »

This Annual Statistical Dossier offers a summary of Pfizer Czech Republic's performance between 2002 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Pfizer Czech Republic at a Glance

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin),

Read more »

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals.

This report offers a summary of the company's performance in 2002-2011. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Pfizer Czech Republic in Numbers

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin),

Read more »

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals.

This excel file offers a summary of the company's performance in 2002-2011. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic had the biggest debt relative to its equity at the end of 2017 followed by Bayer Czech Republic and Pfizer Czech Republic.

Sanofi-Aventis Czech

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic had the biggest debt relative to its equity at the end of 2017 followed by Bayer Czech Republic and Pfizer Czech Republic.

Sanofi-Aventis Czech Republic net debt reached CZK 774 mil. and accounted for 103% of equity at the end of 2017. The ratio is down 55.7% when compared to the previous year. Historically, the firm’s net debt to equity reached an all time high of 336% in 2004 and an all time low of 57.8% in 2015.

When compared to EBITDA, net debt amounted to 15.3x at the end of the year. The ratio reached an all time high of 29.5x in 2004 and an all time low of 4.16x in 2005.

Comparing Sanofi-Aventis Czech Republic with its closest peers, Bayer Czech Republic posted net debt to equity of 94.4% and 2.49x when compared to EBITDA at the end of 2017. Pfizer Czech Republic ended the year 2016 with a net debt at 24.2% of equity and 2.10x when compared to its EBITDA while Novartis Czech Republic had net debt at 7.85% of equity and 0.371x to EBITDA at the end of the year.

You can see all the companies net debt/equity data on the Net Debt/Equity indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Bayer Czech Republic generated the highest earnings before interest cost, taxes and depreciation (so called EBITDA) in 2017 followed by Pfizer Czech Republic and Novartis Czech Republic.

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Bayer Czech Republic generated the highest earnings before interest cost, taxes and depreciation (so called EBITDA) in 2017 followed by Pfizer Czech Republic and Novartis Czech Republic.

Bayer Czech Republic made EBITDA of CZK 158 mil, down 32.3% compared to the previous year. Historically, the firm’s EBITDA reached an all time high of CZK 233 mil in 2016 and an all time low of CZK -10.0 mil in 2007. The average profit in the last five years amounted to CZK 167 mil.

The company generated an average EBITDA margin of 4.11% for its shareholders in the last five years with a maximum of 5.38% and a minimum of 3.53%.

Comparing Bayer Czech Republic with its closest peers, Pfizer Czech Republic generated EBITDA of CZK 156 mil with a EBITDA margin of 4.36% in 2017, Novartis Czech Republic grossed CZK 138 mil (EBITDA margin of 2.18%) and GlaxoSmithKline Czech Republic announced a profit of CZK 97.4 mil translating into a margin of 3.36%.

You can see all the companies ebitda data on the EBITDA indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Amgen Czech Republic generated the highest EBIIDA Margin in 2017 followed by Pfizer Czech Republic and Merck Czech Republic.

Amgen Czech Republic made EBITDA of CZK 49.0

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Amgen Czech Republic generated the highest EBIIDA Margin in 2017 followed by Pfizer Czech Republic and Merck Czech Republic.

Amgen Czech Republic made EBITDA of CZK 49.0 mil, which translates into EBITDA margin of 11.8%. Historically, the firm’s margin reached an all time high of 13.8% in 2011 and an all time low of 6.20% in 2016. The average EBITDA margin in the last five years amounted to 8.59%.

Comparing Amgen Czech Republic with its closest peers, Pfizer Czech Republic generated EBITDA of CZK 156 mil with a EBITDA margin of 4.36% in 2017, Merck Czech Republic grossed CZK 72.8 mil (EBITDA margin of 4.00%) and Bayer Czech Republic announced a profit of CZK 158 mil translating into a margin of 3.77%.

You can see all the companies ebitda margin data on the EBITDA Margin indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic generated the highest sales in 2017 followed by Novartis Czech Republic and Bayer Czech Republic.

Sanofi-Aventis Czech Republic made total sales

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic generated the highest sales in 2017 followed by Novartis Czech Republic and Bayer Czech Republic.

Sanofi-Aventis Czech Republic made total sales of CZK 7,268 mil, up 8.47% compared to the previous year. Historically, the firm’s revenues an all time high of CZK 7,525 mil in 2010 and an all time low of CZK 2,045 mil in 2004.

The average sales growth in the last five years amounted to 0.118%.

Comparing Sanofi-Aventis Czech Republic with its closest peers, Novartis Czech Republic generated a sales of CZK 6,312 mil average sales growth 9.94% in 2017, Bayer Czech Republic sold products and services worth CZK 4,180 mil (5-year growth of 5.19%) and Pfizer Czech Republic announced revenues of CZK 3,586 mil translating into average nominal growth of 5.19% in the last five years.

You can see all the companies sales data on the Sales indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

See all charts of the company »
Pfizer CR's net profit rose 39.7% to CZK 103 mil in 2017
Pfizer CR's employees rose 51.0% to 219 in 2017
Pfizer CR's Total Cash From Operations fell 2,773% to CZK -700 mil in 2017
Pfizer CR's Net Margin rose 26.4% to 2.86% in 2017
Pfizer CR's Net Debt/EBITDA rose 4,530% to 2.10 in 2017
Pfizer CR's ROCE rose 13.7% to 6.11% in 2017
Pfizer CR's Capital Expenditures rose 630% to CZK 142 mil in 2017
Pfizer CR's Cash & Cash Equivalents rose 56.5% to CZK 8.88 mil in 2017